Wei‐Bang Yu

502 total citations
15 papers, 402 citations indexed

About

Wei‐Bang Yu is a scholar working on Molecular Biology, Immunology and Physiology. According to data from OpenAlex, Wei‐Bang Yu has authored 15 papers receiving a total of 402 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 7 papers in Immunology and 3 papers in Physiology. Recurrent topics in Wei‐Bang Yu's work include Phagocytosis and Immune Regulation (6 papers), Erythrocyte Function and Pathophysiology (3 papers) and Immune cells in cancer (3 papers). Wei‐Bang Yu is often cited by papers focused on Phagocytosis and Immune Regulation (6 papers), Erythrocyte Function and Pathophysiology (3 papers) and Immune cells in cancer (3 papers). Wei‐Bang Yu collaborates with scholars based in China and Macao. Wei‐Bang Yu's co-authors include Jin‐Jian Lu, Min Huang, Xiuping Chen, Chuncao Xu, Jiajie Shi, Mu‐Yang Huang, Jing Jin, Zhongxiang Zhao, Jing Jin and Di Cao and has published in prestigious journals such as Biochemical Pharmacology, Advanced Science and Drug Discovery Today.

In The Last Decade

Wei‐Bang Yu

14 papers receiving 391 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Wei‐Bang Yu China 11 161 98 60 48 44 15 402
Jiajie Luan China 14 205 1.3× 89 0.9× 77 1.3× 21 0.4× 67 1.5× 31 505
Harilal Patel India 13 202 1.3× 52 0.5× 75 1.3× 22 0.5× 68 1.5× 46 512
Sebastian Maxeiner Germany 17 320 2.0× 57 0.6× 52 0.9× 50 1.0× 57 1.3× 40 582
Jing Hao China 9 133 0.8× 57 0.6× 53 0.9× 19 0.4× 45 1.0× 33 453
Miao Qiu China 11 204 1.3× 62 0.6× 127 2.1× 26 0.5× 26 0.6× 21 429
Jiaojiao Liang China 13 277 1.7× 47 0.5× 46 0.8× 46 1.0× 66 1.5× 19 537
Qingling Li China 11 186 1.2× 62 0.6× 77 1.3× 18 0.4× 80 1.8× 40 515
Mahmoud El‐Daly Egypt 15 177 1.1× 51 0.5× 38 0.6× 65 1.4× 25 0.6× 40 601

Countries citing papers authored by Wei‐Bang Yu

Since Specialization
Citations

This map shows the geographic impact of Wei‐Bang Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wei‐Bang Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wei‐Bang Yu more than expected).

Fields of papers citing papers by Wei‐Bang Yu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wei‐Bang Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wei‐Bang Yu. The network helps show where Wei‐Bang Yu may publish in the future.

Co-authorship network of co-authors of Wei‐Bang Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Wei‐Bang Yu. A scholar is included among the top collaborators of Wei‐Bang Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wei‐Bang Yu. Wei‐Bang Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Ye, Zihan, Wei‐Bang Yu, Mu‐Yang Huang, et al.. (2025). Repurposing Cardiac Glycosides to Potentiate CD47 Blockade through Calreticulin‐mediated Phagocytic Effects for Lung Cancer Treatment. Advanced Science. 12(46). e08245–e08245.
2.
Yu, Wei‐Bang, et al.. (2025). Dual blockade of GSTK1 and CD47 improves macrophage-mediated phagocytosis on cancer cells. Biochemical Pharmacology. 236. 116898–116898. 1 indexed citations
3.
Yu, Wei‐Bang, et al.. (2022). Building on the backbone of CD47-based therapy in cancer: Combination strategies, mechanisms, and future perspectives. Acta Pharmaceutica Sinica B. 13(4). 1467–1487. 28 indexed citations
4.
Yu, Wei‐Bang, Yu‐Chi Chen, Shi Wei, et al.. (2022). CD47 blockade improves the therapeutic effect of osimertinib in non-small cell lung cancer. Frontiers of Medicine. 17(1). 105–118. 7 indexed citations
5.
Zhao, Hong, Jin‐Jian Lu, Shi Wei, et al.. (2022). Identification of AHSA1 as a Potential Therapeutic Target for BreastCancer: Bioinformatics Analysis and in vitro Studies. Current Cancer Drug Targets. 22(2). 142–152. 3 indexed citations
6.
Jiang, Xiaoming, Mu‐Yang Huang, Yulian Xu, et al.. (2021). Regulation of CD47 expression by interferon-gamma in cancer cells. Translational Oncology. 14(9). 101162–101162. 27 indexed citations
7.
8.
Jiang, Xiaoming, Yulian Xu, Mu‐Yang Huang, et al.. (2020). Licochalcone A inhibits interferon-gamma-induced programmed death-ligand 1 in lung cancer cells. Phytomedicine. 80. 153394–153394. 42 indexed citations
9.
Yu, Wei‐Bang, et al.. (2020). The development of small-molecule inhibitors targeting CD47. Drug Discovery Today. 26(2). 561–568. 57 indexed citations
10.
Cai, Dake, et al.. (2019). Simultaneous determination of curcumin, tetrahydrocurcumin, quercetin, and paeoniflorin by UHPLC-MS/MS in rat plasma and its application to a pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis. 172. 58–66. 27 indexed citations
11.
Chen, Yibei, Ziyi Zhou, Guoming Li, et al.. (2018). Influences of an NR1I2 polymorphism on heterogeneous antiplatelet reactivity responses to clopidogrel and clinical outcomes in acute ischemic stroke patients. Acta Pharmacologica Sinica. 40(6). 762–768. 16 indexed citations
12.
Yu, Wei‐Bang, et al.. (2018). Simultaneous determination of trimethylamine N -oxide, choline, betaine by UPLC–MS/MS in human plasma: An application in acute stroke patients. Journal of Pharmaceutical and Biomedical Analysis. 152. 179–187. 30 indexed citations
13.
Xu, Chuncao, Di Cao, Wei‐Bang Yu, et al.. (2018). Inhibition of Glucose-6-Phosphate Dehydrogenase Reverses Cisplatin Resistance in Lung Cancer Cells via the Redox System. Frontiers in Pharmacology. 9. 43–43. 49 indexed citations
14.
Bai, Xupeng, Yibei Chen, Chuncao Xu, et al.. (2017). Valproate induced hepatic steatosis by enhanced fatty acid uptake and triglyceride synthesis. Toxicology and Applied Pharmacology. 324. 12–25. 34 indexed citations
15.
Liu, Rui, Ziyi Zhou, Yibei Chen, et al.. (2016). Associations of CYP3A4, NR1I2, CYP2C19 and P2RY12 polymorphisms with clopidogrel resistance in Chinese patients with ischemic stroke. Acta Pharmacologica Sinica. 37(7). 882–888. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jiajie Luan Breakdown of academic impact, for papers by Harilal Patel Breakdown of academic impact, for papers by Sebastian Maxeiner Breakdown of academic impact, for papers by Jing Hao Breakdown of academic impact, for papers by Miao Qiu Breakdown of academic impact, for papers by Jiaojiao Liang Breakdown of academic impact, for papers by Qingling Li Breakdown of academic impact, for papers by Mahmoud El‐Daly
Rankless by CCL
2026